CEO: Dan Myers
Ticker: Nasdaq: ALIM
Alimera is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s efforts are focused on diseases affecting the lining in the back of the eye, or retina, as these diseases are either not treated pharmacologically or are in need of improved treatments. Alimera held an inital public offering in April 2010.